Takayuki Kii

Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer

Tomoya Yokota, Ken Kato, Yasuo Hamamoto et al. · British Journal of Cancer · 2016 · 146 citations · Full text

Medicine, Oncology, Surgery +14

Phase I/<scp>II</scp> trial of 2‐weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (<scp>JCOG</scp>0807)

Shuichi Hironaka, Yasuhiro Tsubosa, Junki Mizusawa et al. · Cancer Science · 2014 · 71 citations · Full text

Medicine, Oncology, Pharmacology +15

A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma

Hironaga Satake, Makoto Tahara, Satoshi Mochizuki et al. · Cancer Chemotherapy and Pharmacology · 2016 · 64 citations · Full text

Medicine, Oncology, Surgery +16

Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)

Hironaga Satake, Takeshi Kato, Koji Oba et al. · The Oncologist · 2020 · 63 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer

Tomoya Yokota, Ken Kato, Yasuo Hamamoto et al. · Annals of Surgical Oncology · 2019 · 60 citations

Medicine, Oncology, Surgery +9